C
URGN icon

Covestor’s UroGen Pharma URGN Stock Holding History

Covestor’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
+6
New +$120 ﹤0.01% 2799
2025
Q4 		– Sell
-68
Closed -$1K – 2763
2025
Q3 		$1K Buy
+68
New +$1.22K ﹤0.01% 2197

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Covestor's URGN Position: Q1 2026 in Review

Covestor opened a new position in UroGen Pharma (URGN) in Q1 2026: 6 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2799 among its holdings. This is a return to the name: Covestor previously reported a position in URGN as recently as Q3 2025.

Covestor first reported a position in URGN in Q3 2025 and has held it in 2 quarters since. The position peaked at $1K in Q3 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Covestor held 6 shares of UroGen Pharma worth $0 as of Q1 2026.
  • UroGen Pharma was a new Covestor position in Q1 2026.
  • UroGen Pharma made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2799 holding.
  • Covestor first reported a position in UroGen Pharma in Q3 2025 and has held it in 2 quarters since.
  • Covestor's UroGen Pharma position peaked at $1K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.